Endothelial progenitor cells: New perspectives and applications in cardiovascular therapies

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 687-701

  Marsboom, Glenn ^a   Janssens, Stefan ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cardiovascular disease; Endothelial progenitor cell; EPC dysfunction; EPC transplantation

Indexed keywords

ANTIOXIDANT; BETA2 INTEGRIN; CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE DONOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SCATTER FACTOR; SOMATOMEDIN; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; BIOLOGICAL MARKER;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CLONE; CELL COUNT; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL GROWTH; CELL HOMING; CELL ISOLATION; CELL LOSS; CELL POPULATION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HINDLIMB; HUMAN; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LEG ISCHEMIA; MONONUCLEAR CELL; MORBIDITY; MORTALITY; MULTIPOTENT STEM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARACRINE SIGNALING; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; REGENERATIVE MEDICINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL MOBILIZATION; TISSUE REGENERATION; TISSUE REPAIR; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UMBILICAL CORD BLOOD; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; DISEASE MODEL; FORECASTING; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; METHODOLOGY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RAT; REGENERATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FORECASTING; HUMANS; MICE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PROGNOSIS; RATS; REGENERATION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 47149090755     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.687     Document Type: Review

References (92)

1. Risau W, Flamme I. Vasculogenesis. Annu. Rev. Cell Dev. Biol. 11, 73-91 (1995).
2. McGrath KE, Koniski AD, Malik J, Palis J. Circulation is established in a stepwise pattern in the mammalian embryo. Blood 101(5), 1669-1676 (2003).
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6(4), 389-395 (2000).
4. Leung DW, Cachianes G, Kuang WJ, Goeddel DV. Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (NY) 246(4935), 1306-1309 (1989).
5. Shi Q, Wu MH, Hayashida N et al. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J. Vasc. Surg. 20(4), 546-556; discussion 556-547 (1994).
6. Scott SM, Barth MG, Gaddy LR, Ahl ET Jr. The role of circulating cells in the healing of vascular prostheses. J. Vasc. Surg. 19(4), 585-593 (1994).
7. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science (NY) 275(5302), 964-967 (1997).
8. +) cells identifies a population of functional endothelial precursors. Blood 95(3), 952-958 (2000).
9. Eichmann A, Corbel C, Nataf V et al. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc. Natl Acad. Sci. USA 94(10), 5141-5146 (1997).
10. + hematopoietic precursors. Arterioscler. Thromh. Vasc. Biol. 27(7), 1572-1579 (2007).
11. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia 21(6), 1141-1149 (2007).
12. Kalka. C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA 97(7), 3422-3427 (2000).
13. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107(8), 1164-1169 (2003).
14. Hur J, Yoon CH, Kim HS et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler. Thromb. Vasc. Biol. 24(2), 288-293 (2004).
15. Gulati R, Jevremovic D, Peterson TE et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ. Res. 93(11), 1023-1025 (2003).
16. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol. 51(6), 660-668 (2008).
17. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105(1), 71-77 (2000).
18. De Meyer SF, Vanhoorelbeke K, Chuah MK et al. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 107(12), 4728-4736 (2006).
19. Shi Q, Rafii S, Wu MH et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92(2), 362-367 (1998).
20. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85(3), 221-228 (1999).
21. Gunsilius E, Duba HC, Petzer AL et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355(9216), 1688-1691 (2000).
22. Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109(5), 1801-1809 (2007).
23. Aicher A, Rentsch M, Sasaki K et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ. Res. 100(4), 581-589 (2007).
24. Hillebrands JL, Klatter FA, van Dijk WD, Rozing J. Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat. Med. 8(3), 194-195 (2002).
25. Urbich C, Aicher A, Heeschen C et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39(5), 733-742 (2005).
26. Cho HJ, Lee N, Lee JY et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J. Exp. Med. 204(13), 3257-3269 (2007).
27. Li Q, Li B, Wang X et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wail stress, and cardiac hypertrophy. J. Clin. Invest. 100(8), 1991-1999 (1997).
28. Nakamura T, Mizuno S, Matsumoto K et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106(12), 1511-1519 (2000).
29. Badorff C, Brandes RP, Popp R et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 107(7), 1024-1032 (2003).
30. Koyanagi M, Urbich C, Chavakis E et al. Differentiation of circulating endothelial progenitor cells to a cardiomyogenic phenotype depends on E-cadherin. FEBS Lett. 579(27), 6060-6066 (2005).
31. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103(5), 634-637 (2001).
32. Chavakis E, Aicher A, Heeschen C et al. Role of β2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J. Exp. Med. 201(1), 63-72 (2005).
33. Yoon CH, Hur J, Park KW et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 112(11), 1618-1627 (2005).
34. Dubois C, Marsboom G, Depelteau H et al. Intracoronary mesenchymal stem cell or endothelial progenitor cell transfer post myocardial infarction prevents negative remodeling but fails to enhance global functional recovery. J. Am. Coll. Cardiol. 55th Annual Scientific Session (Abstract Suppl. 1), 47, A180 (2006)
35. Gulad R, Jevremovic D, Peterson TE et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 108(12), 1520-1526 (2003).
36. Werner N, Junk S, Laufs U et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res. 93(2), e17-e24 (2003).
37. George J, Afek A, Abashidze A et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 25(12), 2636-2641 (2005).
38. Nagaya N, Kangawa K, Kanda M et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108(7), 889-895 (2003).
39. Zhao YD, Courtman DW, Deng Y et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ. Res. 96(4), 442-450 (2005).
40. Takahashi M, Nakamura T, Toba T et al. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tiss. Eng. 10(5-6), 771-779 (2004).
41. Marsboom G, Pokreisz P, Gheysens O et al. Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells 26(4), 1017-1026 (2008).
42. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7(11), 1194-1201 (2001).
43. Assmus B, Schachinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106(24), 3009-3017 (2002).
44. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol. 44(8), 1690-1699 (2004).
45. Bartunek J, Vanderheyden M, Vandekerckhove B et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 112(9 Suppl.), 1178-1183 (2005).
46. Erbs S, Linke A, Adams V et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ. Res. 97(8), 756-762 (2005).
47. Assmus B, Honold J, Schachinger V et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 355(12), 1222-1232 (2006).
48. Wang XX, Zhang FR, Shang YP et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J. Am. Coll. Cardiol. 49(14), 1566-1571 (2007).
49. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 83(1), 356-362 (1991).
50. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348(7), 593-600 (2003).
51. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89(1), E1-E7 (2001).
52. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353(10), 999-1007 (2005).
53. George J, Herz I, Goldstein E et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler. Thromb. Vasc. Biol. 23(12), e57-e60 (2003).
54. Galasso G, Schiekofer S, Sato K et al. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circ. Res. 98(2), 254-261 (2006).
55. Laufs U, Werner N, Link A et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109(2), 220-226 (2004).
56. Rehman J, Li J, Parvathaneni L et al. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/ macrophage-derived angiogenic cells. J. Am. Coll. Cardiol. 43(12), 2314-2318 (2004).
57. Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5(4), 434-438 (1999).
58. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103(23), 2776-2779 (2001).
59. +) endothelial precursor cells. Circ. Res. 88(2), 167-174 (2001).
60. Powell TM, Paul JD, Hill JM et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 25(2), 296-301 (2005).
61. Cho HJ, Kim HS, Lee MM et al. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation 108(23), 2918-2925 (2003).
62. Hiasa K, Ishibashi M, Ohtani K et al. Gene transfer of stromal cell-derived factor-1α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109(20), 2454-2461 (2004).
63. Hattori K, Dias S, Heissig B et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193(9), 1005-1014 (2001).
64. Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18(14), 3964-3972 (1999).
65. Kalka C, Masuda H, Takahashi T et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res. 86(12), 1198-1202 (2000).
66. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4), 1340-1346 (2003).
67. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103(24), 2885-2890 (2001).
68. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105(25), 3017-3024 (2002).
69. Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108(3), 399-405 (2001).
70. Pistrosch F, Herbrig K, Oelschlaegel U et al. PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183(1), 163-167 (2005).
71. Wang CH, Ting MK, Verma S et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J. 152(6), 1051 e1-e8 (2006).
72. Min TQ, Zhu CJ, Mang WX, Hui ZJ, Peng SY; International Society of Cardiovascular Pharmacotherapy Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 18(3), 203-209 (2004).
73. Thum T, Hoeber S, Froese S et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ. Res. 100(3), 434-443 (2007).
74. Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9(11), 1370-1376 (2003).
75. Sasaki K, Heeschen C, Aicher A et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc. Natl Acad. Sci. USA 103(39), 14537-14541 (2006).
76. Iwaguro H, Yamaguchi J, Kalka C et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105(6), 732-738 (2002).
77. Wu Y, Ip JE, Huang J et al. Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circ. Res. 99(3), 315-322 (2006).
78. Yoon CH, Hur J, Oh IY et al. Intercellular adhesion molecule-1 is upregulated in ischemic muscle, which mediates trafficking of endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 26(5), 1066-1072 (2006).
79. Walter DH, Haendeler J, Reinhold J et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ. Res. 97(11), 1142-1151 (2005).
80. Yamaguchi J, Kusano KF, Masuo O et al. Stromal cell-derived Factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107(9), 1322-1328 (2003).
81. Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10(8), 858-864 (2004).
82. Aicher A, Brenner W, Zuhayra M et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 107(16), 2134-2139 (2003).
83. DiFabio JM, Thomas GR, Zucco L et al. Nitroglycerin attenuates human endothelial progenitor cell differentiation, function, and survival. J. Pharmacol. Exp. Ther. 318(1), 117-123 (2006).
84. Thum T, Fraccarollo D, Schultheiss M et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes, 56(3), 666-674 (2007).
85. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505), 113-121 (2006).
86. Schachinger V, Erbs S, Usasser A et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J. 27(23), 2775-2783 (2006).
87. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1199-1209 (2006).
88. Hoetzer GL, Van Guilder GP, Irmiger HM et al. Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men. J. Appl. Physiol. 102(3), 847-852 (2007).
89. Loomans CJ, de Koning EJ, Staal FJ et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of Type 1 diabetes. Diabetes 53(1), 195-199 (2004).
90. Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from Type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106(22), 2781-2786 (2002).
91. Choi JH, Kim KL, Huh W et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler. Thromb. Vasc. Biol. 24(7), 1246-1252 (2004).
92. Kondo T, Hayashi M, Takeshita K et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler. Thromb. Vasc. Biol. 24(8), 1442-1447 (2004).